Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
复制标题
Figo I-II 期卵巢透明细胞癌的临床和生物学特征。
DOI：
--
复制
发表时间：
2005
影响因子：
5.2
通讯作者：
B. Sorbe
中科院分区：
文献类型：
--
作者：
I. Skirnisdottir;T. Seidal;M. Karlsson;B. Sorbe
卵巢透明细胞癌被认为是上皮性卵巢恶性肿瘤中的一个特殊亚型。为了表征早期FIGO阶段（I-II）透明细胞癌的临床和生物学特性，进行了一项回顾性研究，将这些肿瘤与其他组织学亚型进行比较。从226例FIGO I-II期上皮性卵巢癌患者的完整系列中，选择了28例透明细胞癌患者，并将这些肿瘤的临床和生物学特征与其余非透明细胞癌进行比较。所有患者均行一期剖腹手术，随后进行辅助放疗或化疗。免疫组化法检测细胞凋亡调控因子p53、bcl-2、bax和生长因子受体EGFR、HER-2/neu的表达，流式细胞术检测细胞DNA。透明细胞癌染色阴性p53显着高于其他组织学亚型。EGFR阳性表达在浆液性癌中较透明细胞癌多见。非整倍体DNA状态在透明细胞癌中比其他组织学亚型更常见，四倍体肿瘤占非二倍体肿瘤的50%。透明细胞肿瘤经常（64%）出现在FIGO分期IC和IIC，这比非透明细胞肿瘤更常见。透明细胞癌和非透明细胞癌患者的肿瘤复发率或生存率无差异。卵巢透明细胞癌应被视为上皮性卵巢癌中的一个独立实体，与非透明细胞肿瘤相比，它们在临床和生物学特征方面都有所不同。
Clear cell carcinoma of the ovary is considered to be a specific subtype among the epithelial ovarian malignancies. To characterize clear cell carcinomas in early FIGO stages (I-II) with regard to clinical and biological properties, a retrospective study was performed to compare these tumors with other histological subtypes. From a complete series of 226 patients with epithelial ovarian carcinomas in FIGO stages I-II, 28 patients with clear cell carcinomas were selected and the clinical and biological characteristics of these tumors were compared with the remaining non-clear cell carcinomas. All patients underwent primary staging laparotomy followed by adjuvant radiotherapy or chemotherapy. The apoptosis regulators p53, bcl-2 and bax, and the growth factor receptors EGFR and HER-2/neu were analyzed by immunohistochemical techniques and DNA analysis was performed by flow cytometry. Clear cell carcinomas stained negative for p53 significantly more often than other histological subtypes. Positive EGFR staining was seen more frequently in serous carcinomas than in the clear cell carcinomas. Aneuploid DNA status was seen more frequently in clear cell carcinomas than in other histological subtypes and tetraploid tumors made up 50% of the non-diploid tumors. Clear cell tumors were frequently (64%) found in FIGO stages IC and IIC and this was more common than for non-clear cell tumors. No difference was found in the rate of tumor recurrences or survival for patients with clear cell and non-clear cell carcinomas. Clear cell carcinomas of the ovary should be regarded as a separate entity among the epithelial ovarian carcinomas and they differ with regard to both clinical and biological characteristics when compared with non-clear cell tumors.